Advertisement

Hyperuricemia and Associated Diseases

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Rheumatic Disease Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Fessel J.W.
        Renal outcomes of gout and hyperuricemia.
        Am J Med. 1979; 67: 74-82
        • Liang M.H.
        • Fries J.F.
        Asymptomatic hyperuricemia: the case for conservative management.
        Ann Intern Med. 1978; 88: 666-670
        • Wyngaarden J.B.
        • Kelley W.N.
        Gout and hyperuricemia. Grune & Stratton, New York1976
        • Gibson T.
        • Waterworth R.
        • Hatfield P.
        • et al.
        Hyperuricemia, gout and kidney function in New Zealand Maori men.
        Br J Rheumatol. 1984; 23: 276-282
        • Darmavan J.
        • Valkenburg H.A.
        • Muirden K.D.
        • et al.
        The epidemiology of gout and hyperuricemia in a rural population of Java.
        J Rheumatol. 1992; 19: 1595-1599
        • Ko Y.C.
        • Wang T.N.
        • Tsai L.Y.
        • et al.
        High prevalence of hyperuricemia in adolescent Taiwan aborigenes.
        J Rheumatol. 2002; 29: 837-842
        • Klemp P.
        • Stansfield S.A.
        • Castle B.
        • et al.
        Gout is on the increase in New Zealand.
        Ann Rheum Dis. 1997; 56: 22-26
        • Jossa F.
        • Farinaro E.
        • Panico S.
        • et al.
        Serum uric acid and hypertension: the Olivetti heart study.
        J Hum Hypertens. 1994; 8: 677-681
        • Masuo K.
        • Kawaguchi H.
        • Mikami H.
        • et al.
        Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation.
        Hypertension. 2003; 42: 474-480
        • Taniguchi Y.
        • Hayashi T.
        • Tsumura K.
        • et al.
        Serum uric acid and the risk of hypertension and type 2 diabetes in Japanese men. The Osaka health study.
        J Hypertens. 2001; 19: 1209-1215
        • Nakanishi N.
        • Okamato M.
        • Yoshida H.
        • et al.
        Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers.
        Eur J Epidemiol. 2003; 18: 523-530
        • Hunt S.C.
        • Stephenson S.H.
        • Hopkins P.N.
        • et al.
        Predictors of an increased risk of future hypertension in Utah. A screening analysis.
        Hypertension. 1991; 17: 969-976
        • Grahame R.
        • Scott J.T.
        Clinical survey of 354 patients with gout.
        Ann Rheum Dis. 1970; 29: 461-468
        • Rapado A.
        Relationship between gout and arterial hypertension.
        Adv Exp Med Biol. 1974; 41B: 451-459
        • Kahn H.A.
        • Medalie J.H.
        • Neufeld H.N.
        • et al.
        The incidence of hypertension and associated factors: the Israel ischemic heart disease study.
        Am Heart J. 1972; 84: 171-182
        • Prebis J.W.
        • Gruskin A.B.
        • Polinsky M.S.
        • et al.
        Uric acid in childhood essential hypertension.
        J Pediatr. 1981; 98: 702-707
        • Messerli F.H.
        • Frohlich E.D.
        • Dreslinski G.R.
        • et al.
        Serum uric acid in essential hypertension: an indicator of renal vascular involvement.
        Ann Intern Med. 1980; 93: 817-821
        • Puig J.G.
        • Miranda M.E.
        • Mateos F.A.
        • et al.
        Hereditary nephropathy associated with hyperuricemia and gout.
        Arch Intern Med. 1993; 153: 357-365
        • Kanellis J.
        • Watanabe S.
        • Li J.H.
        • et al.
        Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen activated protein kinase and cyclooxygenase-2.
        Hypertension. 2003; 41: 1287-1293
        • Kanellis J.
        • Kang D.H.
        Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease.
        Semin Nephrol. 2005; 25: 39-42
        • Mazzali M.
        • Hughes J.
        • Kim Y.G.
        • et al.
        Elevated uric acid increases blood pressure in the rat by a novel crystal independent mechanism.
        Hypertension. 2001; 38: 1101-1106
        • Mazzali M.
        • Kanellis J.
        • Han L.
        • et al.
        Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure independent mechanism.
        Am J Physiol Renal Physiol. 2002; 282: F991-F997
        • Watanabe S.
        • Kang D.H.
        • Feng L.
        • et al.
        Uric acid, hominoid evolution and the pathogenesis of salt- sensitivity.
        Hypertension. 2002; 40: 355-360
        • Feig D.I.
        • Johnson R.J.
        Hyperuricemia in childhood essential hypertension.
        Hypertension. 2003; 42: 247-252
        • Feig D.I.
        • Nakagawa T.
        • Karumanchi S.A.
        • et al.
        Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension.
        Kidney Int. 2004; 66: 1-8
        • Johnson R.J.
        • Tuttle K.R.
        Much ado about nothing, or much to do about something? The continuing controversy over the role of uric acid in cardiovascular disease.
        Hypertension. 2000; 35: E10
        • Johnson R.J.
        • Kang D.H.
        • Feig D.
        • et al.
        Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?.
        Hypertension. 2003; 41: 1183-1190
        • Johnson R.J.
        • Rodriguez-Iturbe B.
        • Kang D.H.
        • et al.
        A unifying pathway for essential hypertension.
        AJH. 2005; 18: 431-440
        • Feig D.I.
        Uric acid and hypertension in adoloscents.
        Semin Nephrol. 2005; 25: 32-38
        • Kang D.H.
        • Nakagawa T.
        Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease.
        Semin Nephrol. 2005; 25: 43-49
        • Sanchez-Lozada L.G.
        • Tapia E.
        • Avila-Casado C.
        • et al.
        Mild hyperuricemia induces glomerular hypertension in normal rats.
        Am J Physiol Renal Physiol. 2002; 283: F1105-F1110
        • Nakagawa T.
        • Mazzali M.
        • Kang D.H.
        • et al.
        Hyperuricemia causes glomerular hypertrophy in the rat.
        Am J Nephrol. 2003; 23: 2-7
        • Kang D.H.
        • Nakawaga T.
        • Feng L.
        • et al.
        A role of uric acid in the progression of renal disease.
        J Am Soc Nephrol. 2002; 13: 2888-2897
        • Kang D.H.
        • Nakagawa T.
        Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease.
        Semin Nephrol. 2005; 25: 43-49
        • Sanchez-Lozada L.
        • Tapia E.
        • Rodriguez-Iturbe B.
        • et al.
        Hemodynamics of hyperuricemia.
        Semin Nephrol. 2005; 25: 19-24
        • Mazzali M.
        • Kim Y.-G.
        • Suga S.
        • et al.
        Hyperuricemia exacerbates chronic cyclosporine nephropathy.
        Transplantation. 2001; 71: 900-905
        • Reif M.C.
        • Constantiner A.
        • Levitt M.F.
        Chronic gouty nephropathy: a vanishing syndrome.
        N Engl J Med. 1981; 304: 535-536
        • Fairbanks L.D.
        • Cameron J.S.
        • Venkat-Raman G.
        • et al.
        Early treatment with allopurinol in familial juvenile hyerpuricaemic nephropathy (FJHN) ameliorates the long-term progression of renal disease.
        Q J Med. 2002; 95: 597-607
        • McBride M.B.
        • Simmonds H.A.
        • Ogg C.S.
        • et al.
        Efficacy of allopurinol in ameliorating the progressive renal disease in familial juvenile hyperuricaemic nephropathy (FJHN). A six-year update.
        Adv Exp Med Biol. 1998; 431: 7-11
        • Cameron J.S.
        • Simmonds H.A.
        Hereditary hyperuricemia and renal disease.
        Semin Nephrol. 2005; 25: 9-18
        • Dahan K.
        • Vuyst D.
        • Smaers M.
        • et al.
        A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with anornal expression of uromodulin.
        J Am Soc Nephrol. 2003; 14: 2883-2893
        • Segura J.
        • Campo C.
        • Ruilope L.M.
        How relevant and frequent is the presence of mild renal insufficiency in essential hypertension?.
        J Clin Hypertens. 2002; 4: 332-336
        • Leoncini G.
        • Viazzi F.
        • Parodi D.
        • et al.
        Mild renal dysfunction and subclinical cardiovascular damage in primary hypertension.
        Hypertension. 2003; 42: 14-18
        • Staessen J.
        • for members of the European working party on high blood pressure in the elderly
        The determinants and prognostic significance of serum uric acid in elderly patients of the European working party on high blood pressure in the elderly trial.
        Am J Med. 1991; 90: 50s-54s
        • Tomita M.
        • Mizuno S.
        • Yamanaka H.
        • et al.
        Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers.
        J Epidemiol. 2000; 10: 403-409
        • Iseki K.
        • Oshiro S.
        • Tozawa M.
        • et al.
        Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects.
        Hyprtens Res. 2001; 24: 691-697
        • Perlstein T.S.
        • Gumieniak O.
        • Hopkins P.N.
        • et al.
        Uric acid and the state of the intrarenal renin angiotensin system in humans.
        Kidney Int. 2004; 66: 1465-1470
        • Iseki K.
        • Ikemiya Y.
        • Inoue T.
        • et al.
        Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort.
        Am J Kidney Dis. 2004; 44: 642-650
        • Johnson R.J.
        • Kivlighn S.D.
        • Kim Y.G.
        • et al.
        Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular, and renal disease.
        Am J Kidney Dis. 1999; 33: 225-234
        • Alderman M.H.
        • Cohen H.
        • Madhavan S.
        • et al.
        Serum uric acid and cardiovascular events in successfully treated hypertensive patients.
        Hypertension. 1999; 34: 144-150
        • Brand F.N.
        • McGee D.L.
        • Kannel W.B.
        • et al.
        Hyperuricemia as a risk factor of coronary heart disease: the Framingham study.
        Am J Epidemiol. 1985; 121: 11-18
        • Abbott R.D.
        • Brand F.N.
        • Kannel W.B.
        • et al.
        Gout and coronary heart disease: the Framingham study.
        J Clin Epidemiol. 1988; 41: 237-242
        • Culleton B.F.
        • Larson M.
        • Kannel W.B.
        • et al.
        Serum uric acid and risk for cardiovascular disease and death: the Framingham heart study.
        Ann Intern Med. 1999; 131: 7-13
        • Wannamethee S.G.
        • Shaper A.G.
        • Whincup P.H.
        Serum urate and the risk of major coronary heart disaese events.
        Heart. 1997; 78: 147-153
        • Nagahama K.
        • Iseki K.
        • Inoue T.
        • et al.
        Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan.
        Hypertens Res. 2004; 27: 227-233
        • Fang J.
        • Alderman M.H.
        Serum uric acid and cardiovascular mortality. The NHANES I epidemiologic follow up study, 1971–1992.
        JAMA. 2000; 283: 2404-2410
        • Bickel C.
        • Rupprecht H.J.
        • Blankenberg S.
        • et al.
        Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease.
        Am J Cardiol. 2002; 89: 12-17
        • Yusuf S.
        • Bosch J.
        Urate levels as predictor of cardiac deaths: causal relation or mere association?.
        Eur Heart J. 2002; 23: 760-761
        • Wong K.Y.
        • MacWalter R.S.
        • Fraser H.W.
        • et al.
        Urate predicts subsequent cardiac death in stroke survivors.
        Eur Heart J. 2002; 23: 788-793
        • Tuttle K.R.
        • Short R.A.
        • Johnson R.J.
        Sex differences in uric acid and risk factors for coronary artery disease.
        Am J Cardiol. 2001; 87: 1411-1414
        • Rich M.W.
        Uric acid: is it a risk factor for cardiovascular disease?.
        Am J Cardiol. 2000; : 1018-1021
        • Madsen T.E.
        • Muhlestein J.B.
        • Carlquist J.F.
        • et al.
        Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease.
        Am J Nephrol. 2005; 25: 45-49
        • Moriarity J.T.
        • Folsom A.R.
        • Iribarren C.
        • et al.
        Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk In Communities (ARIC) Study.
        Ann Epidemiol. 2000; 10: 136-143
        • Freedman D.S.
        • Williamson D.F.
        • Gunter E.W.
        • et al.
        Relation of serum uric acid to mortality and Ischemic heart disease. The NHANES 1 Epidemiologic Follow-up study.
        Am J Epidemiol. 1995; 141: 637-644
        • Liese A.D.
        • Hense H.W.
        • Lowel H.
        • et al.
        Association of serum uric acid with all- cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg Cohort.
        Epidemiology. 1999; 10: 391-397
        • Franse L.V.
        • Pahor M.
        • Bari M.D.
        • et al.
        Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP).
        J Hypertens. 2000; 18: 1149-1154
        • Verdecchia P.
        • Schillaci G.
        • Reboldi G.
        • et al.
        Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study.
        Hypertension. 2000; 36: 1072-1078
        • Niskanen L.K.
        • Laaksonen D.E.
        • Nyyssonen K.
        • et al.
        Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle aged men.
        Arch Intern Med. 2004; 164: 1546-1551
        • Hoieggen A.
        • Alderman M.H.
        • Kjeldsen S.E.
        • et al.
        The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
        Kidney Int. 2004; 65: 1041-1049
        • Dahlof B.
        • Devereux R.
        • de Faire U.
        • et al.
        The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
        Am J Hypertens. 1997; 10: 705-713
        • Athyros V.G.
        • Elisaf M.
        • Papageorgiou A.A.
        • et al.
        Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary artery disease: a subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.
        Am J Kidney Dis. 2004; 43: 589-599
        • Malinow M.R.
        • Levenson J.
        • Giral P.
        • et al.
        Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyteine concentration.
        Atherosclerosis. 1995; 114: 175-183
        • Hong Y.S.
        • Lee M.J.
        • Kim K.H.
        • et al.
        The C677 mutation in methylene tetrahydrofolate reductase gene: Correlation with uric acid and cardiovascular risk factors in elderly korean men.
        J Korean Med Sci. 2004; 19: 209-213
        • Mercuro G.
        • Vitale C.
        • Cerquetani E.
        • et al.
        Effect of hyperuricemia upon endothelial function in patients with increased cardio vascular risk.
        Am J Cardiol. 2004; 94: 932-935
        • Gavin A.R.
        • Struthers A.D.
        Hyperuricemia and adverse outcomes in cardiovascular disease.
        Am J Cardiovasc Drugs. 2005; 3: 309-314
        • Yu Z.F.
        • Bruce-Keller A.J.
        • Goodman Y.
        • et al.
        Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo.
        J Neurosci Res. 1998; 53: 613-625
        • Chamorro A.
        • Obach V.
        • Cervera A.
        • et al.
        Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke.
        Stroke. 2002; 33: 1048-1052
        • Lehto S.
        • Niskanen L.
        • Ronnemaa T.
        • et al.
        Serum uric acid is a strong predictor of stroke in patients with non-insulin dependent diabetes mellitus.
        Stroke. 1998; 29: 635-639
        • Mazza A.
        • Pessina A.C.
        • Pavei A.
        • et al.
        Predictors of stroke mortality in elderly people from the general population.
        Eur J Epidemiol. 2001; 17: 1097-1104
        • Wang J.G.
        • Staessen J.A.
        • Fagard R.H.
        • et al.
        Prognostic significance of serum creatinine and uric acid in older chinese patients with isolated systolic hypertension.
        Hypertension. 2001; 37: 1069-1074
        • Weir C.J.
        • Muir S.W.
        • Walters M.R.
        • et al.
        Serum urate as an independent predictor of poor outome and future vascular events after acute stroke.
        Stroke. 2003; 34: 1951-1956
        • Abuja P.M.
        Ascorbate prevents pro oxidant effects of urate in oxidation of human low density lipoprotein.
        FEBS Lett. 1999; 446: 305-308
        • Cherubini A.
        • Polidori M.C.
        • Bregnocchi M.
        • et al.
        Antioxidant profile and early outcome in stroke patients.
        Stroke. 2000; 31: 2295-2300
        • Tseng C.H.
        Independent association of uric acid levels with peripheral arterial disease in Taiwanese patients with Type 2 diabetes.
        Diabet Med. 2004; 21: 724-729
        • Nieto F.J.
        • Iribarren C.
        • Gross M.D.
        • et al.
        Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?.
        Atherosclerosis. 2000; 148: 131-139
        • Doehner W.
        • Schoene N.
        • Rauchhaus M.
        • et al.
        Effects of xanthine oxidase inhibition with allopurinol on endothelialfunction and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo controlled studies.
        Circulation. 2002; 105: 2619-2624
        • Anker S.D.
        • Doehner W.
        • Rauchhaus M.
        • et al.
        Uric acid and survival in chronic heart failure.
        Circulation. 2003; 107: 1991-1997
        • Cicoira M.
        • Zanolla L.
        • Rossi A.
        • et al.
        Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy.
        Am Heart J. 2002; 143: 1107-1111
        • Hare J.M.
        • Johnson R.J.
        Uric acid predicts clinical outcomes in heart failure. Insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology.
        Circulation. 2003; 107: 1951-1953
        • Cappola T.P.
        • Kass D.A.
        • Nelson G.S.
        • et al.
        Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy.
        Circulation. 2001; 104: 2407-2411
        • Ekelund U.E.
        • Harrison R.W.
        • Shokek O.
        • et al.
        Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing induced heart failure.
        Circ Res. 1999; 85: 437-445
        • Ukai T.
        • Cheng C.P.
        • Tachibana H.
        • et al.
        Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing induced heart failure.
        Circulation. 2001; 103: 750-755
        • Struthers A.D.
        • Donnan P.T.
        • Lindsay P.
        • et al.
        Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospcetive cohort study.
        Heart. 2002; 87: 229-234
        • Emmerson B.
        Hyperlipidaemia in hyperuricaemia and gout.
        Ann Rheum Dis. 1998; 58: 509-510
        • Facchini F.
        • Chen Y.-D.
        • Hollenbeck C.B.
        • et al.
        Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration.
        JAMA. 1991; 266: 3008-3011
        • Vuorin-Markkola H.
        • Yki-Jarvonen H.
        Hyperuricemia and insulin-resistance.
        J Clin Endocrinol Metab. 1994; 78: 25-29
        • Reaven G.M.
        Role of insulin-resistance in human disease.
        Diabetes. 1988; 37: 1596-1607
        • Denzer C.
        • Muche R.
        • Mayer H.
        • et al.
        Serum uric acid levels in obese children and adolscents:linkage to testosterone levels and pre metabolic syndome.
        J Pediatr Endocrinol. 2003; 16: 1225-1232
        • Gokcel A.
        • Gumurdulu Y.
        • Karakose H.
        • et al.
        Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
        Diabetes Obes Metab. 2002; 4: 49-55
        • Brauer G.W.
        • Prior I.A.M.
        A prospective study of gout in New Zealand Maoris.
        Ann Rheum Dis. 1978; 37: 466-472
        • Fessel W.J.
        • Bar G.D.
        Uric acid, lean body weight and creatine interactions: results from regression analysis of 78 variables.
        Semin Arthritis Rheum. 1977; 7: 115-121
        • Glynn R.J.
        • Campion E.W.
        • Silbert J.E.
        Trends in serum uric acid levels 1961–1980.
        Arthritis Rheum. 1983; 26: 87-93
        • Scott J.T.
        Obesity and hyperuricaemia.
        Clin Rheum Dis. 1977; 3: 25-35
        • Sturge R.A.
        • Scott J.T.
        • Kennedy A.C.
        • et al.
        Serum uric acid in England and Scotland.
        Ann Rheum Dis. 1977; 36: 420-427
        • Seidell J.C.
        • Bakx K.C.
        • Deurenberg P.
        • et al.
        Overweight and chronic illness: a retrospective cohort study with a follow-up of 6–17 years, in men and women of initially 20–50 years of age.
        J Chronic Dis. 1986; 39: 585-593
        • Must A.
        • Jacques P.F.
        • Dallal G.E.
        • et al.
        Long term morbidity and mortality of overweight adolescents. A follow up of the Harvard Growth Study of 1922 to 1935.
        N Engl J Med. 1992; 327: 1379-1380
        • Loenen H.M.
        • Eshuis H.
        • Lowik M.R.
        • et al.
        Serum uric acid correlates in elderly men and women with special reference to body composition and dietary intake (Dutch Nutrition Surveillance System).
        J Clin Epidemiol. 1990; 43: 1297-1303
        • Bray G.A.
        Complications of obesity.
        Ann Intern Med. 1985; 103: 1052-1062
        • Emmerson B.T.
        Alteration of urate metabolism by weight reduction.
        Aust N Z J Med. 1973; 3: 410-412
        • Gibson T.
        • Waterworth R.
        • Hatfield P.
        • et al.
        Hyperuricaemia, gout and kidney function in New Zealand Maori men.
        Br J Rheumatol. 1984; 23: 276-282
        • Kannel W.B.
        • Gordon T.
        Physiological and medical concomittants of obesity: the Framingham study.
        in: Bray G.A. Obesity in America. DHEW (PHS) Publication 79-359, Bethesda (MD)1979: 125-163
        • Roubenoff R.
        • Klag M.J.
        • Mead L.A.
        • et al.
        Incidence and risk factors for gout in white men.
        JAMA. 1991; 266: 3004-3007
        • Ogura T.
        • Matsuura K.
        • Matsumoto Y.
        • et al.
        Recent trends of hyperuricemia and obseity in Japanese male adolescents, 1991 through 2002.
        Metabolism. 2004; 53: 448-453
        • Masuo K.
        • Kawaguchi H.
        • Mikami H.
        • et al.
        Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation.
        Hypertension. 2003; 42: 474-480
        • Reynolds P.P.
        • Knapp M.J.
        • Baraf H.S.B.
        • et al.
        Moonshine and lead. Relationship to the pathogenesis and hyperuricemia in gout.
        Arthritis Rheum. 1983; 26: 1057-1064
        • Dessein P.H.
        • Shipton E.A.
        • Stanwix A.E.
        • et al.
        Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study.
        Ann Rheum Dis. 2000; 59: 539-543
        • Tsunoda S.
        • Kamide K.
        • Minami J.
        • et al.
        Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: Effect of a low energy diet and an insulin sensitizing agent.
        Am J Hypertens. 2002; 15: 697-701
        • Tambascia M.A.
        • Geloneze B.
        • Repetto E.M.
        • et al.
        Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double blind, randomised controlled trial.
        Diabetes Obes Metab. 2003; 5: 338-344
        • Krejs G.J.
        Metabolic benefits associated with sibutramine therapy.
        Int J Obes Relat Metab Disord. 2002; 26: S34-S37
        • Sjostrom L.
        • Lindroos A.K.
        • Peltonen M.
        • et al.
        Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.
        N Engl J Med. 2004; 351: 2683-2693
        • Donahue R.P.
        • Prineas R.
        • Donahue D.C.
        • et al.
        Is fasting leptin associated with insulin resistance among nondiabetic individuals? The Miami community health study.
        Diabetes Care. 1999; 22: 1092-1096
        • Ruige J.B.
        • Dekker J.
        • Blum W.F.
        • et al.
        Leptin and variables of body adiposity, energy balance, and Insulin resistance in a population based study: the Hoorn study.
        Diabetes Care. 1999; 22: 1097-1104
        • Ogura T.
        • Matsura K.
        • Otsuka F.
        • et al.
        Serum leptin correlates with serum uric acid but not with serum testosterone in non obese male adolescents.
        Res Commun Mol Pathol Pharm. 2000; 107: 55-63
        • Garcia-Lorda P.
        • Bullo M.
        • Vila R.
        • et al.
        Leptin concentrations do not correlate with fat mass nor with metabolic risk factors in morbidly obese females.
        Diab Nutr Metab. 2001; 14: 329-336
        • Matsubara M.
        • Chiba H.
        • Maruoka S.
        • et al.
        Elevated serum leptin concentrations in women with hyperurecemia.
        J Atheroscler Thromb. 2002; 9: 28-34
        • Bedir A.
        • Topbas M.
        • Tanyeri F.
        • et al.
        Leptin might be a regulator of serum uric acid concentrations in humans.
        Jpn Heart J. 2002; 44: 527-536
        • Moreno L.A.
        • Pineda I.
        • Rodriguez G.
        • et al.
        Leptin and metabolic syndrome in obese and non obese children.
        Horm Metab Res. 2002; 34: 394-399
        • Barlow K.A.
        Hyperlipidemia in primary gout.
        Metabolism. 1968; 17: 289-299
        • Gibson J.T.
        • Grahame R.
        Gout, hypertriglyceridemia, and alcohol consumption.
        Ann Rheum Dis. 1974; 33: 109-110
        • Naito H.K.
        • Mackenzie A.H.
        Secondary hypertriglyceridemia and hyperlipoproteinemia in patients with primary asymptomatic gout.
        Clin Chem. 1979; 25: 371-375
        • Jiao S.
        • Kameda K.
        • Matsuzawa Y.
        • et al.
        Hyperlipoproteinemia in primary gout: hyperlipoproteinemic phenotype and influence of alcohol intake and obesity in Japan.
        Ann Rheum Dis. 1986; 45: 308-313
        • Daskalopoulou S.S.
        • Mikhailidis D.P.
        • Elisaf M.
        Prevention and treatment of the metabolic syndrome.
        Angiology. 2004; 55: 589-612
        • Takahashi S.
        • Yamamoto T.
        • Moriwaki Y.
        • et al.
        Impaired lipoprotein metabolism in patients with primary gout: influence of alcohol intake and body weight.
        Br J Rheumatol. 1994; 33: 731-734
        • Takahashi S.
        • Yamamoto T.
        • Moriwaki Y.
        • et al.
        Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout.
        Ann Rheum Dis. 1995; 54: 90-93
        • Cardona F.
        • Tinahones F.J.
        • Collantes E.
        • et al.
        The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates.
        Rheumatol. 2003; 42: 468-472
        • Clausen J.O.
        • Borch-Johnsen K.
        • Ibsen H.
        • et al.
        Analysis of the relationship between fasting seum uric acid and the insulin sensitivity index in a population based sample of 380 young healthy caucasians.
        Eur J Endocrinol. 1998; 138: 63-69
        • Rocic B.
        • Vucic-Lovrencic M.
        • Poje N.
        • et al.
        Uric acid may inhibit glucose induced insulin secretion via binding to an arginine residue in rat pancreatic beta cells.
        Bioorg Med Chem Lett. 2005; 15: 1181-1184
        • Hara H.
        • Egusa G.
        • Yamakido M.
        Incidence of non insulin dependent diabetes mellitus and its risk factors in Japanese Americans living in Hawaii and Los Angeles.
        Diabet Med. 1996; 13: S133-S142
        • Lin K.C.
        • Tsai S.T.
        • Lin H.Y.
        • et al.
        Different progressions of hyperglycemia and diabetes among hyperuricemic men and women in the Kinmen study.
        J Rheumatol. 2004; 31: 1159-1165
        • Chou P.
        • Lin-Chia L.
        • Wu G.S.
        • et al.
        Progression of type 2 diabetes among high risk groups in Kin-Chen kinmen.
        Diabetes Care. 1998; 21: 1183-1187
        • Nakanishi N.
        • Okamato M.
        • Yoshida H.
        • et al.
        Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers.
        Eur J Epidemiol. 2003; 18: 523-530